Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database

Ôshima, Yasuo; Takahashi, Satoshi; Tani, Kenzaburo; Tojo, Arinobu

doi:10.1016/j.cyto.2019.02.013

Cited by 56 publications

(67 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among patients who received tripegfilgrastim, which is a biosimilar of pegfilgrastim, no aortitis occurred. According to previous studies including data from Japan ADR database 6 , 8 – 20 , the biosimilars of G-CSF did not cause aortitis. Taken together, although the mechanism is unknown, biosimilars of G-CSF can be the alternatives when G-CSF administration is inevitable for patients.…”

Section: Discussionmentioning

confidence: 91%

“…Therefore, considering the fact that most of the breast cancer patients undergoes chemotherapy with PEGylated filgrastim, aortitis could occur more easily in breast cancer patients. However, for breast cancer, few data pertained to G-CSF-related aortitis including several case reports 6 , 8 – 15 , 17 – 19 and two study from Adverse Drug Reporting (ADR) systems 16 , 20 . Data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) reported that the frequency of G-CSF-related aortitis was 0.0014% 20 .…”

Section: Discussionmentioning

confidence: 99%

“…Data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) reported that the frequency of G-CSF-related aortitis was 0.0014% 20 . Another data based on the Japanese ADR database reported the incidence of G-CSF-induced aortitis as 0.47% 20 . Although those two results showed the association between G-CSF injection and the development of aortitis, they included the patients with malignancy and not exposed to chemotherapy with G-CSF in study population and did not report the detailed clinical courses including treatment of aortitis.…”

Section: Discussionmentioning

confidence: 99%

“…Filgrastim and lenograstim, which is a short-acting agent of G-CSF, have very similar biological structure and activity compared to endogenous human G-CSF; PEGylated filgrastim is a long-acting agent of G-CSF 7 . According to cases reported to date, several types of G-CSF (filgrastim, lenograstim, lipegfilgrastim and PEGylated filgrastim) can cause aortitis in patients with various types of malignancies 6 , 8 – 20 . The exact incidence of G-CSF related aortitis is unknown; however, it was more frequently detected in patients with breast cancer, ovarian cancer or lymphoma 20 .…”

Section: Introductionmentioning

confidence: 99%

“…According to cases reported to date, several types of G-CSF (filgrastim, lenograstim, lipegfilgrastim and PEGylated filgrastim) can cause aortitis in patients with various types of malignancies 6 , 8 – 20 . The exact incidence of G-CSF related aortitis is unknown; however, it was more frequently detected in patients with breast cancer, ovarian cancer or lymphoma 20 . In particular, PEGylated filgrastim, usually used for primary prophylaxis of neutropenia in breast cancer patients, is known to be associated with the highest incidence of aortitis among G-CSF agents.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer

Lee

Kim

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Although PEGylated filgrastim-induced aortitis is very rare and unknown clinically, some cases were reported and increasing, especially in breast cancer patients. The present study investigated the prevalence, clinical features and treatment of aortitis induced by PEGylated filgrastim in patients with breast cancer. A total of 2068 consecutive patients who underwent neoadjuvant/adjuvant chemotherapy with PEGylated filgrastim for breast cancer were enrolled. From the medical record, clinical, laboratory, medication, and imaging evaluation findings were collected. PEGylated filgrastim-induced aortitis was established in 0.3% of the study population. Common clinical presentations included extremely high fever and chest/back pain with high levels of inflammatory markers without any signs of infection. Contrast-enhanced computed tomography scans revealed typical enhancing wall thickening and periaortic soft tissue infiltration at various levels of aorta. All patients improved rapidly after treatment with modest doses of prednisolone (0.5 mg/kg/day) without any complications. Clinicians should be aware of aortitis as a possible complication of granulocyte-colony stimulating factor therapy, especially PEGylated filgrastim, given the frequent misdiagnoses in neutropenic patients undergoing chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer

Lee

Kim

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

Can immunological manipulation defeat SARS‐CoV‐2? Why G‐CSF induced neutrophil expansion is worth a clinical trial

Katayama¹

2020

BioEssays

View full text Add to dashboard Cite

Immunity against SARS‐CoV‐2 that is acquired by convalescent COVID‐19 patients is examined in reference to (A) the Th17 cell generation system in psoriatic epidermis and (B) a recently discovered phenomenon in which Th17 cells are converted into tissue‐resident memory T (TRM) cells with Th1 phenotype. Neutrophils that are attracted to the site of infection secrete IL‐17A, which stimulates lung epithelial cells to express CCL20. Natural Th17 (nTh17) cells are recruited to the infection site by CCL20 and expand in the presence of IL‐23. These nTh17 cells are converted to TRM cells upon encounter with SARS‐CoV‐2 and continue to exist as ex‐Th17 cells, which exert Th1‐like immunity during a memory response. G‐CSF can induce nTh17 cell accumulation at the infection site because it promotes neutrophil egress from the bone marrow. Hence, G‐CSF may be effective against COVID‐19. Administration of G‐CSF to patients infected with SARS‐CoV‐2 is worth a clinical trial.

show abstract

Development of papulonodular eruptions in a patient with granulocyte colony‐stimulating factor‐induced leukocytoclastic vasculitis: A case report

Sakai

Nomura

2022

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

We report herein the case of a 62-year-old woman who had been suffering from multiple myeloma for 4 years. The patient was started on subcutaneous injection of lenograstim, a recombinant granulocyte-colony-stimulating factor (G-CSF), for chemotherapyinduced neutropenia (leukocyte count: 760/μl; absolute neutrophil count (ANC): 661/μl). Despite the treatment, the ANC decreased to 12/μl on day 6. On day 12, she developed a reddish papule with mild tenderness on the right cheek, followed by the appearance of similar lesions on the face and extremities, without any apparent preceding skin lesions. She was referred to the dermatology division on day 20. Physical examination revealed discrete or grouped, light or bright red, hemispherical hard papules and nodules up to 8 mm in size on the face and extremities (Figure 1A-C). Some of the nodules were ulcerated. Purpura was not observed. At this point, the ANC was 888/μl. The immunoglobulin G level was 4688 mg/dl (normal: 800-1800 mg/dl) 15 days before the first lenograstim injection, and it remained high at 3787 mg/dl 10 days after the cessation of lenograstim. Anti-neutrophil cytoplasmic antibodies were not tested.Skin biopsy showed a dense neutrophilic infiltrate with few lymphocytes in the upper dermis accompanied by a large amount of nuclearThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database

Cited by 56 publications

References 12 publications

The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer

The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer

Can immunological manipulation defeat SARS‐CoV‐2? Why G‐CSF induced neutrophil expansion is worth a clinical trial

Development of papulonodular eruptions in a patient with granulocyte colony‐stimulating factor‐induced leukocytoclastic vasculitis: A case report

Contact Info

Product

Resources

About